



# ACCP

AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY®  
Advancing Clinical Care through Pharmacology®

## Symposia

**WEDNESDAY, SEPTEMBER 23, 2020 | Symposium 20 | 2:00 – 6:00 PM**

### *Transporter-mediated Drug-Drug Interactions, Current Status & Future Perspectives: An ACCP/ISSX Jointly-sponsored Symposium*

**BASIC SCIENCE OF CLINICAL PHARMACOLOGY TRACK**

*Offers both CME & CPE Credit*

**UAN #JA4008220-9999-20-032-H04-P**

**ACPE – 3.5 CONTACT HOURS/KNOWLEDGE-BASED**

**CHAIR:**

**Yanke Yu, PhD**, Director, Clinical Pharmacology, Pfizer Inc

**TARGET AUDIENCE:**

This Symposium will be useful for graduate students, postdoctoral fellows/trainees and professionals in the field of pharmacy, pharmacometrics, clinical pharmacology and clinical pharmacy practice seeking a more in-depth understanding of transporter-mediated drug-drug interactions. This Symposium is applicable to participants across academia, the pharmaceutical industry and regulatory agencies.

**GOALS & OBJECTIVES:**

Following the completion of this activity, the learner will be able to:

1. Compare different regulatory bodies' (US Food & Drug Administration, European Medicines Agency) requirements for transporter-mediated drug-drug interactions (DDI);
2. Understand current industrial and regulatory perspective on the role of the animal model, mechanistic static model and physiologically-based pharmacokinetic modeling approaches in prediction and assessment of transporter-mediated DDI;
3. Understand the current status of endogenous transporter biomarkers;
4. Understand the current status of pharmacogenomics of drug transporters.

---

#### **Overview of Transporter-mediated Drug-Drug Interaction (DDI)**

*Yanke Yu, PhD, Director, Clinical Pharmacology, Pfizer Inc*

---

#### **Evolution of Regulatory Guidance (US Food & Drug Administration) on Transporter-mediated DDI**

*Xinning Yang, PhD, Policy Lead, CDER/OTS/OCP, US Food & Drug Administration*

---

#### **European Medicines Agency's Perspectives on Transporter-mediated DDI**

*Carolien Versantvoort, PhD, Clinical Pharmacology Assessor, Medicines Evaluation Board, European Medicines Agency*

---

#### **Pharmacogenomics of Drug Transporters & Its Clinical Implication**

*Kathleen M. Giacomini, PhD, Professor, Univ of California San Francisco*

---

#### **Preclinical Tools to Quantitatively Predict Transporter DDIs: Mechanistic Static Models & In Vivo Animal Models**

*Manthena Varma, PhD, Associate Research Fellow, Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc*

---

#### **Endogenous Biomarkers for Assessing Transporter-mediated DDIs**

*Manoli Vourvahis, PharmD, Senior Director, Clinical Pharmacology, Pfizer Inc*

---

#### **Modeling & Simulation of Transporter-mediated DDI: A View from an Industry/ Consortium Transporter Focus Group**

*Venkatesh Pilla Reddy, PhD, Associate Principal Scientist, AstraZeneca plc*

---

#### **The Application of Physiologically-based Pharmacokinetic Modeling in Evaluating Transporter-mediated DDI: A Regulatory Science Perspective**

*Xinyuan Zhang, PhD, PBPK Lead, Pharmacometrics/OCP/OTS/CDER, US Food & Drug Administration*

---

#### **Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluation**